Compare DOMO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | GNLX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 110.4M |
| IPO Year | 2018 | 2022 |
| Metric | DOMO | GNLX |
|---|---|---|
| Price | $3.84 | $2.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $10.28 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.2M | 294.1K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | $8,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.84 | $2.29 |
| 52 Week High | $18.49 | $8.54 |
| Indicator | DOMO | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 40.28 |
| Support Level | $3.32 | $2.34 |
| Resistance Level | $4.05 | $2.97 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 75.31 | 14.29 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.